section name header

Indications

REMS

Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

CV: ARRHYTHMIAS, chest pain, HF, hypotension, palpitations, peripheral edema, syncope, tachycardia.

Derm: sweating, dermatitis, ERYTHEMA MULTIFORME, flushing, photosensitivity, pruritus/urticaria, rash, STEVENS-JOHNSON SYNDROME (SJS).

EENT: blurred vision, disturbed equilibrium, epistaxis, tinnitus.

Endo: gynecomastia, hyperglycemia.

GI: liver enzymes, anorexia, constipation, diarrhea, dry mouth, dyspepsia, nausea, vomiting.

GU: dysuria, nocturia, polyuria, sexual dysfunction, urinary frequency.

Hemat: anemia, leukopenia, thrombocytopenia.

Metab: weight.

MS: joint stiffness, muscle cramps.

Neuro: abnormal dreams, anxiety, confusion, dizziness, drowsiness, dysgeusia, headache, nervousness, paresthesia, psychiatric disturbances, tremor, weakness.

Resp: cough, dyspnea.
Misc: gingival hyperplasia.

Interactions

Drug-Drug:

Drug-Natural Products:

Drug-Food:

Availability

(Generic available)

Route/Dosage

Hepatic Impairment

US Brand Names

Nymalize

Action

Therapeutic Effects:

Classifications

Therapeutic Classification:subarachnoid hemorrhage therapy agents

Pharmacologic Classification: calcium channel blockers

Pharmacokinetics

Absorption: Well absorbed following oral administration but undergoes first-pass metabolism, resulting in bioavailability.

Distribution: Crosses the blood-brain barrier; remainder of distribution unknown.

Protein Binding: >95%.

Metabolism/Excretion: Mostly metabolized by the liver; le.gif10% excreted unchanged by kidneys.

Half-life: 1–2 hr.

Canadian Brand Names

Nimotop

Time/Action Profile

(vasodilation)

ROUTEONSETPEAKDURATION
POunknown1 hr4 hr

Patient/Family Teaching

Pronunciation

nye-MOE-di-peen